In his comment [1] on ''Therapies to Preserve b-Cell Function in Type 1 Diabetes'' [2] , Devi Dayal, while overall very positive about the review, suggests that vitamin D deserves a stronger position and claims that the evidence is strong enough to recommend vitamin D in higher doses as part of any future therapy to preserve residual b-cell function, referring to a number of publications. However, well-designed clinical studies so far have not found any effect on b-cell preservation [3, 4] , and this is not refuted by less well-designed small studies with short follow-up that have shown no or insignificant efficacy. There are certainly studies supporting beneficial effects of vitamin D on the immune system, showing improved regulatory T cell function and type 2 T helper cell deviation, which might strengthen therapies in type 1 diabetes. Vitamin D also affects b cells directly, thereby rendering them more resistant to cellular stress [5] . Thus, there is encouraging evidence to include vitamin D in combination therapies. The dose needed to give adequate serum concentrations may vary depending on sun exposure (geography, season, clothing, culture), but 2000 U/day, or perhaps a slightly higher dose, should be safe and still expected to have the desired effects.
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